Importantly, this new link between DYRK2 and HSF1 appears to be relevant in TNBC patients as DYRK2 levels correlate positively with HSF1 nuclear levels, and negatively associate with cancer-specific survival and time to recurrence, supporting a pro-tumoural role for DYRK2 in TNBC. Here, HSF1 is linked to cancer.